AtlasGenomics

Result Report

Specimen ID: ACOV21-094692

Reference ID: LEWSTJUYMVE2U6Q0

Atlas Genomics
2296 W Commodore Way Suite 220
Seattle, WA 98199

Patient: Perman, Robert	**Collection Date: 04/21/2021 13:19**	**Specimen Type: Generic COVID**
DOB: 05/26/1963	**Received Date: 04/21/2021 18:43**	**Test Ordered: SARS-CoV-2, NAA**
Gender: Male	**Collection Site: HealthPoint Administration**	

Additional Patient Information:
Address: 18820 131St Avenue Southeast, Renton, Select 98058
Phone: (206) 391-4820

TEST	RESULT	INTERPRETATION
SARS-CoV-2, NAA	**NEGATIVE***	SARS-CoV-2 RNA was not detected**

*SARS-CoV2 is considered a notifiable condition and as required by applicable state and federal laws including Public Lab 116-136, § 18115(a), the Coronavirus Aid, Relief , and Economic Security (CARES) Act, required patient data and the results of this testing will be reported to the designated public health entity and the Secretary of the Department of Health and Human Services (HHS).

**Refer to the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Inc.) - Fact Sheet for Patients available from the links below, for more information regarding testing, intended use and interpretation of results. For further questions regarding this result, consultation with your primary care physician is recommended.

Patient Fact Sheet Link
https://www.fda.gov/media/136114/download

Provider Fact Sheet Link
https://www.fda.gov/media/136111/download

Methods and Limitations

Method: Detection of SARS-CoV-2 is performed using a multiplex real-time RT-PCR test intended for the presumptive qualitative detection of nucleic acid from SARS-CoV-2. The diagnostic test is also known as a nucleic acid amplification test, or NAAT. All testing is performed in a CLIA-certified clinical laboratory authorized for high complexity testing (Atlas Genomics CLIA # 50D2079714).

Disclaimer: Atlas Genomics implements safeguards to avoid technical errors throughout the testing process. Atlas Genomics is not responsible for errors in specimen collection, transportation, and/or other errors made prior to receipt at our laboratory.

1. An anterior nares or mid-turbinate specimen collected by a healthcare professional or self-collected by the patient is acceptable when the patient is in an appropriate clinical setting or under appropriate observation.
2. This test is not yet approved or cleared by the United States FDA. When there are no FDA-approved or cleared tests available and other criteria are met, FDA can make tests available under an emergency access mechanism called an Emergency Use Authorization (EUA), for use in authorized laboratories. The EUA for this test is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics for the detection and/or diagnosis of the virus that causes COVID-19. This EUA will remain in effect for the duration of the COVID-19 declaration justifying emergency of IVDs, under Section 564(b)(1) of the Act 21, U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Medical Director

Michael Kalnoski